Ad
related to: non nucleoside reverse transcriptase drugs
Search results
Results from the WOW.Com Content Network
Non-nucleoside reverse-transcriptase inhibitors (NNRTIs) are the third class of antiretroviral drugs that were developed. In all cases, patents remain in force until beyond 2007. This class of drugs was first described at the Rega Institute for Medical Research . [citation needed] Efavirenz has the trade names Sustiva and Stocrin.
Non-nucleoside reverse-transcriptase inhibitors (NNRTIs) are antiretroviral drugs used in the treatment of human immunodeficiency virus . NNRTIs inhibit reverse transcriptase (RT), an enzyme that controls the replication of the genetic material of HIV. RT is one of the most popular targets in the field of antiretroviral drug development.
Nucleoside reverse-transcriptase inhibitors (NRTI) and nucleotide reverse-transcriptase inhibitors (NtRTI) are nucleoside and nucleotide analogues which inhibit reverse transcription. HIV is an RNA virus, so it can not be integrated into the DNA in the nucleus of the human cell unless it is first "reverse" transcribed into DNA.
Rilpivirine, sold under the brand names Edurant and Rekambys, is a medication, developed by Tibotec, used for the treatment of HIV/AIDS. [5] [6] It is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs such as efavirenz.
Etravirine is a human immunodeficiency virus type 1 (HIV-1) non-nucleoside reverse transcriptase inhibitor (NNRTI). [1] Unlike agents in the class, resistance to other NNRTIs does not seem to confer resistance to etravirine. [4] Etravirine is marketed by Janssen, a subsidiary of Johnson & Johnson.
Elsulfavirine (trade name Elpida; also known as VM 1500) is drug used to treat HIV infection. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI). [1] [2] [3] Elsulfavirine is a prodrug which is metabolized to the active antiviral agent deselsulfavirine (also known as VM 1500A). [4] It was developed by the Russian company Viriom. [5]
Pages in category "Non-nucleoside reverse transcriptase inhibitors" The following 14 pages are in this category, out of 14 total. This list may not reflect recent changes .
It is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and works by blocking the function of reverse transcriptase. [5] Nevirapine was approved for medical use in the United States in 1996. [5] It is on the World Health Organization's List of Essential Medicines. [7] It is available as a generic medication. [5]
Ad
related to: non nucleoside reverse transcriptase drugs